Pluri (NASDAQ:PLUR) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Pluri (NASDAQ:PLUR) released its quarterly earnings data on Thursday. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.11, FiscalAI reports. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.66 million.

Pluri Stock Performance

Shares of Pluri stock opened at $3.40 on Friday. The business’s 50 day simple moving average is $3.35 and its 200 day simple moving average is $3.42. Pluri has a 52-week low of $2.82 and a 52-week high of $5.96. The firm has a market cap of $36.62 million, a PE ratio of -0.69 and a beta of 0.75.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.00.

Institutional Investors Weigh In On Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC bought a new stake in Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned about 0.14% of Pluri as of its most recent filing with the SEC. 16.59% of the stock is owned by hedge funds and other institutional investors.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.